Stockscreener 앱 받기
157.69
2.38%
3.67
시간 외 거래:
158.74
1.05
+0.67%
전일 마감가:
$154.02
열려 있는:
$155
하루 거래량:
222.51K
Relative Volume:
1.19
시가총액:
$6.32B
수익:
-
순이익/손실:
$-77.61M
주가수익비율:
-68.62
EPS:
-2.2979
순현금흐름:
-
1주 성능:
+2.41%
1개월 성능:
+10.00%
6개월 성능:
-3.96%
1년 성능:
+168.96%
1일 변동 폭
$154.25
$158.90
1주일 범위
$140.99
$158.90
52주 변동 폭
$58.77
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
157.69 | 6.17B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK) - The Globe and Mail
BLTE - Finviz
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Nigeria
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):